MDxHealth Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

MDxHealth wird ein Gewinn- und Umsatzwachstum von 59.8% bzw. 15.5% pro Jahr prognostiziert, während der Gewinn pro Aktie um 66.7% pro Jahr wachsen soll.

Wichtige Informationen

59.8%

Wachstumsrate der Gewinne

66.7%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	36.0%
Wachstumsrate der Einnahmen	15.5%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	18 Dec 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Why Investors Shouldn't Be Surprised By MDxHealth SA's (EBR:MDXH) 29% Share Price Plunge

Oct 05

Gewinn- und Umsatzwachstumsprognosen

ENXTBR:MDXH - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	96	-13	-3	1	4
12/31/2024	82	-26	-20	-15	5
12/31/2023	70	-43	-26	-20	5
9/30/2023	64	-45	-30	-24	N/A
6/30/2023	55	-48	-35	-29	N/A
3/31/2023	46	-47	-34	-30	N/A
12/31/2022	37	-44	-38	-34	N/A
9/30/2022	30	-40	-32	-30	N/A
6/30/2022	25	-34	-28	-26	N/A
3/31/2022	23	-31	N/A	N/A	N/A
12/31/2021	22	-29	-23	-23	N/A
9/30/2021	21	-28	-22	-21	N/A
6/30/2021	19	-28	-21	-21	N/A
3/31/2021	19	-28	N/A	N/A	N/A
12/31/2020	18	-29	-21	-20	N/A
9/30/2020	15	-36	-20	-20	N/A
6/30/2020	11	-43	-20	-20	N/A
3/31/2020	11	-43	-21	-21	N/A
12/31/2019	12	-43	-22	-22	N/A
9/30/2019	17	-37	-25	-25	N/A
6/30/2019	22	-31	-28	-27	N/A
3/31/2019	25	-32	-29	-28	N/A
12/31/2018	28	-32	-30	-29	N/A
9/30/2018	31	-30	-30	-28	N/A
6/30/2018	33	-28	-31	-27	N/A
3/31/2018	37	-20	-23	-19	N/A
12/31/2017	41	-12	-15	-10	N/A
9/30/2017	41	-9	-13	-8	N/A
6/30/2017	41	-5	N/A	-5	N/A
3/31/2017	36	-9	N/A	-11	N/A
12/31/2016	30	-13	N/A	-17	N/A
9/30/2016	26	-15	N/A	-17	N/A
6/30/2016	23	-17	N/A	-16	N/A
3/31/2016	20	-16	N/A	-15	N/A
12/31/2015	18	-14	N/A	-14	N/A
9/30/2015	16	-14	N/A	-15	N/A
6/30/2015	15	-13	N/A	-15	N/A
3/31/2015	13	-14	N/A	-17	N/A
12/31/2014	12	-15	N/A	-19	N/A
9/30/2014	10	-16	N/A	-19	N/A
6/30/2014	8	-16	N/A	-19	N/A
3/31/2014	8	-16	N/A	-17	N/A
12/31/2013	8	-16	N/A	-14	N/A
9/30/2013	7	-15	N/A	-13	N/A
6/30/2013	7	-14	N/A	-12	N/A
3/31/2013	7	-13	N/A	-11	N/A
12/31/2012	6	-12	N/A	-11	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MDXH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: MDXH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: MDXH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: MDXHDie Einnahmen des Unternehmens (15.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Belgian (7.2% pro Jahr).

Hohe Wachstumseinnahmen: MDXHDie Einnahmen des Unternehmens (15.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von MDXH in 3 Jahren voraussichtlich hoch sein wird

MDxHealth Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Mdxhealth SA Raises Earnings Guidance for the Year 2024

MDxHealth SA Revises Earnings Guidance for the Year 2024

MDxHealth SA Maintains Earnings Guidance for the Year 2024

MDxHealth SA Provides Earnings Guidance for the Fourth Quarter and Full Year 2023 and Year 2024

MDxHealth SA Provides Earnings Guidance for the Year 2023

MDxHealth SA Revises Earnings Guidance for the Year 2023

Recent updates

MDxHealth SA has filed a Follow-on Equity Offering in the amount of $40 million.

Mdxhealth SA Raises Earnings Guidance for the Year 2024

MDxHealth SA Revises Earnings Guidance for the Year 2024

MDxHealth SA has filed a Follow-on Equity Offering in the amount of $50 million.

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering

MDxHealth SA Maintains Earnings Guidance for the Year 2024

MDxHealth SA Announces Jan Pensaert Steps Down from its Board of Directors

MDxHealth SA Provides Earnings Guidance for the Fourth Quarter and Full Year 2023 and Year 2024

MDxHealth SA to Report Q1, 2024 Results on May 08, 2024

MDxHealth SA Shares No Longer Be Listed and Traded on Euronext Brussels, Effective as of Close of Trading on Euronext Brussels on December 15, 2023

MDxHealth SA Shares No Longer Be Listed and Traded on Euronext Brussels, Effective as of Close of Trading on Euronext Brussels on December 15, 2023

New minor risk - Profitability

MDxHealth SA Provides Earnings Guidance for the Year 2023

MDxHealth SA Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Why Investors Shouldn't Be Surprised By MDxHealth SA's (EBR:MDXH) 29% Share Price Plunge

MDxHealth SA to Report Q3, 2023 Results on Oct 09, 2023

Consensus EPS estimates fall by 10%, revenue upgraded

MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?

New major risk - Share price stability

MDxHealth SA Reaffirms Revenue Guidance for the Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

MDxHealth (EBR:MDXH) Is Carrying A Fair Bit Of Debt

Full year 2022 earnings released: US$0.28 loss per share (vs US$0.24 loss in FY 2021)

Third quarter 2022 earnings released: US$0.078 loss per share (vs US$0.06 loss in 3Q 2021)

MDxHealth SA to Report First Half, 2023 Results on Aug 23, 2023

MDxHealth SA Provides Revenue Guidance for the Fiscal Year 2023

MDxHealth SA Revises Revenue Guidance for the Fiscal Year 2022

Price target increased to €1.20

MDxHealth SA Reaffirms Revenue Guidance for the Year 2022

Third quarter 2022 earnings released: US$0.05 loss per share (vs US$0.059 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.072 loss per share (vs US$0.06 loss in 2Q 2021)

MDxHealth SA (ENXTBR:MDXH) acquired Oncotype DX GPS Prostate Cancer Business from Exact Sciences Corporation (NasdaqCM:EXAS) for $100 million.

MDxHealth SA (ENXTBR:MDXH) acquired Oncotype DX GPS Prostate Cancer Business from Exact Sciences Corporation (NasdaqCM:EXAS) for $100 million.

Mdxhealth Sa Announces Resignation of Rudi Mariën as Non-Executive Director

Palmetto GBA’s MolDX Issues Foundational LCD Covering the Indication for SelectMDx for Prostate Cancer

Is MDxHealth (EBR:MDXH) Using Debt In A Risky Way?

Full year 2021 earnings released

Price target increased to €1.20

MDxHealth SA Provides Revenue Guidance for the Full Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Here's Why MDxHealth (EBR:MDXH) Can Manage Its Debt Despite Losing Money

First half 2021 earnings released: US$0.12 loss per share (vs US$0.18 loss in 1H 2020)

MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?

Full year 2020 earnings released: US$0.34 loss per share (vs US$0.69 loss in FY 2019)

Revenue misses expectations

MDxHealth SA to Report Fiscal Year 2020 Results on Apr 28, 2021

MDxHealth SA to Report Fiscal Year 2020 Results on Mar 03, 2021

MDxHealth SA to Report First Half, 2021 Results on Aug 26, 2021

New 90-day high: €1.07

MDxHealth's (EBR:MDXH) Stock Price Has Reduced 75% In The Past Five Years

New 90-day high: €1.00

Is MDxHealth (EBR:MDXH) Weighed On By Its Debt Load?

Price target raised to €1.00

MDxHealth SA Suspends 2020 Guidance

New 90-day low - €0.69

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken